Cargando…
DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
Radiotherapy is the most widely used cancer treatment and improvements in its efficacy and safety are highly sought-after. Peposertib (also known as M3814), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, effectively suppresses the repair of radiation-induced DNA double-stran...
Autores principales: | Carr, Michael I., Chiu, Li-Ya, Guo, Yige, Xu, Chunxiao, Lazorchak, Adam S., Yu, Huakui, Qin, Guozhong, Qi, Jin, Marelli, Bo, Lan, Yan, Sun, Qing, Czauderna, Frank, Zenke, Frank T., Blaukat, Andree, Vassilev, Lyubomir T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381110/ https://www.ncbi.nlm.nih.gov/pubmed/34980594 http://dx.doi.org/10.1158/1541-7786.MCR-21-0612 |
Ejemplares similares
-
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
por: Haines, Eric, et al.
Publicado: (2021) -
Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022) -
Caspase 9b Drives Cellular Transformation, Lung Inflammation, and Lung Tumorigenesis
por: Kim, Minjung, et al.
Publicado: (2022) -
Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis
por: Mohammed, Sabira, et al.
Publicado: (2023) -
DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
por: Carr, Michael I., et al.
Publicado: (2020)